300639 凱普生物
按盤價 
5.860 -0.100 (-1.678%)
5.860 -0.100 (-1.678%) | 2025/06 - 中期 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -2.238 | -14.600 | 2.876 | 42.609 | 30.516 |
| 總資產報酬率 ROA (%) | -1.991 | -12.656 | 2.254 | 31.460 | 24.044 |
| 投入資產回報率 ROIC (%) | -2.137 | -14.132 | 2.764 | 40.125 | 28.793 | 邊際利潤分析 |
| 銷售毛利率 (%) | 46.982 | 47.675 | 61.029 | 69.364 | 67.633 |
| 營業利潤率 (%) | -38.629 | -100.759 | 3.857 | 39.185 | 40.171 |
| 息稅前利潤/營業總收入 (%) | -47.297 | -102.018 | 2.291 | 37.968 | 39.693 |
| 淨利潤/營業總收入 (%) | -43.530 | -116.532 | 6.203 | 32.193 | 33.106 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 47.501 | 22.935 | 17.449 | 130.114 | 103.498 |
| 價值變動淨收益/利潤總額(%) | -3.682 | -1.105 | 37.870 | 1.003 | 1.949 |
| 營業外收支淨額/利潤總額(%) | 4.313 | 1.350 | -15.710 | -3.069 | -1.570 | 償債能力分析 |
| 流動比率 (X) | 4.989 | 5.041 | 6.255 | 3.229 | 3.767 |
| 速動比率 (X) | 4.801 | 4.892 | 6.059 | 3.142 | 3.550 |
| 資產負債率 (%) | 13.281 | 12.469 | 10.951 | 22.454 | 17.875 |
| 帶息債務/全部投入資本 (%) | 3.271 | 2.057 | 0.729 | 2.261 | 4.518 |
| 股東權益/帶息債務 (%) | 2,902.323 | 4,668.231 | 13,367.960 | 4,194.715 | 2,062.472 |
| 股東權益/負債合計 (%) | 670.214 | 712.904 | 775.256 | 324.196 | 422.329 |
| 利息保障倍數 (X) | 6.828 | -845.860 | -2.198 | -755.637 | 278.471 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 581.436 | 658.279 | 751.262 | 123.204 | 113.309 |
| 存貨周轉天數 (天) | 77.224 | 69.693 | 91.291 | 27.911 | 50.649 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 02/09/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
